» Articles » PMID: 7789645

Bone Loss and Bone Turnover in Diabetes

Overview
Journal Diabetes
Specialty Endocrinology
Date 1995 Jul 1
PMID 7789645
Citations 143
Authors
Affiliations
Soon will be listed here.
Abstract

There have been conflicting reports about the effect of diabetes on bone density. In 1978, we studied 109 patients, 46 with type I and 63 with type II diabetes; approximately 12 years later we restudied 35 of the 66 surviving patients. In the original study, radial bone density did not differ significantly between patients with either type of diabetes but was significantly lower than in nondiabetic control subjects. In eight osteopenic patients, bone formation rate and other histological indexes of osteoblast recruitment and function were markedly depressed compared with those in nondiabetic control subjects. In patients remeasured approximately 2.5 years (41 patients) and approximately 12.5 years (35 patients) after baseline, bone loss had continued at the expected rate in patients with type I diabetes, with maintenance of the same deficit, but was slower than expected in patients with type II diabetes, such that the initial deficit had been completely corrected. In six of the eight patients who had undergone bone biopsy, one with type I and five with type II diabetes, the mean bone mineral density z-score of the spine and femoral neck approximately 12 years later was > 0 and in one subject was significantly higher than normal at both sites. Based on these data and on previous studies, we propose that in patients with diabetes, low bone formation retards bone accumulation during growth, metabolic effects of poor glycemic control lead to increased bone resorption and bone loss in young adults, and low bone turnover retards age-related bone loss.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

THE INDEPENDENT EFFECTS OF TYPE 2 DIABETES MELLITUS AND CHRONIC KIDNEY DISEASE ON BONE TURNOVER MARKERS.

Mogos I, Niculescu D, Dusceac R, Poiana C Acta Endocrinol (Buchar). 2024; 20(1):27-32.

PMID: 39372304 PMC: 11449240. DOI: 10.4183/aeb.2024.27.


Bone Fragility in Diabetes and its Management: A Narrative Review.

Leungsuwan D, Chandran M Drugs. 2024; 84(9):1111-1134.

PMID: 39103693 DOI: 10.1007/s40265-024-02078-5.


Increased Risk of Fracture after Traumatic Amputation: A Nationwide Retrospective Cohort Study.

Cho H, Park J, Kim B, Han K, Choi H, Shin D Healthcare (Basel). 2024; 12(13).

PMID: 38998896 PMC: 11241812. DOI: 10.3390/healthcare12131362.


Current knowledge of bone-derived factor osteocalcin: its role in the management and treatment of diabetes mellitus, osteoporosis, osteopetrosis and inflammatory joint diseases.

Martiniakova M, Biro R, Kovacova V, Babikova M, Zemanova N, Mondockova V J Mol Med (Berl). 2024; 102(4):435-452.

PMID: 38363329 PMC: 10963459. DOI: 10.1007/s00109-024-02418-8.


Osseointegration of implant surfaces in metabolic syndrome and type-2 diabetes mellitus.

Bergamo E, de Oliveira P, Campos T, Bonfante E, Tovar N, Boczar D J Biomed Mater Res B Appl Biomater. 2024; 112(2):e35382.

PMID: 38355936 PMC: 10883641. DOI: 10.1002/jbm.b.35382.